All ASCO GU 2010 News

Page 1 of 2

« start ‹ previous ... 1 2 ... next › end »

Trimodal Preservation Saves Most Bladders Without Rise in Cancer Mortality

S London, 2010 Apr 9, Elsevier Global Medical News

SAN FRANCISCO (EGMN) - Bladder-preserving therapy allows most patients with invasive, nonmetastatic bladder cancer to keep their bladder, while offering long-term survival comparable to that seen with...

Adoption of New, More Costly Prostate Cancer Therapies Precedes Evidence

S London , 2010 Apr 5, Elsevier Global Medical News

SAN FRANCISCO (EGMN) - Use of new, more expensive therapies for prostate cancer increased rapidly during a recent 4-year period, despite a lack of consensus on their effectiveness relative to that of older,...

Men Taking Common Medications Have Reduced PSA Levels

S London, 2010 Mar 31, Elsevier Global Medical News

SAN FRANCISCO (EGMN) - Commonly used medications were associated with clinically important reductions in prostate-specific antigen levels among roughly 2,000 middle-aged and older men in a cross-sectional...

Potential Up-Staging Is Not a Reason to Forgo Partial Nephrectomy for RCC

S London, 2010 Mar 31, Elsevier Global Medical News

SAN FRANCISCO (EGMN) - The decision to perform radical nephrectomy instead of partial nephrectomy for clinically early-stage renal cell carcinoma should not be based on concerns that the cancer will have...

Falling Reimbursement Linked to Less ADT for Localized Prostate Cancer

S London, 2010 Mar 26, Elsevier Global Medical News

SAN FRANCISCO (EGMN) - A cut in Medicare reimbursement for androgen deprivation therapy has selectively reduced use of this therapy in an indication for which evidence of benefit is lacking, researchers...

Reliance on PSA Triggers May Lead to Overtreatment of Prostate Cancer

S London, 2010 Mar 15, Elsevier Global Medical News

SAN FRANCISCO (EGMN) - Men with prostate cancer who are on active surveillance may be overtreated if their clinicians rely strictly on certain commonly used prostate-specific antigen triggers for starting...

Survival Benefit of Sipuleucel-T in Prostate Cancer Appears Durable

S London, 2010 Mar 11, Elsevier Global Medical News

SAN FRANCISCO (EGMN) - The survival benefit seen with the cell-based sipuleucel-T vaccine in men with metastatic, castration-resistant prostate cancer persists in the longer term, according to updated...

Cost-Effectiveness Analysis Favors Cystoscopy Alone for Bladder Cancer Surveillance

S London, 2010 Mar 10, Elsevier Global Medical News

SAN FRANCISCO (EGMN) - Cystoscopy alone offers the best combination of cost and sensitivity for surveillance after treatment of superficial bladder cancer, new data show. In a prospective study comparing...

Novel Urinary Assay Improves Prostate Cancer Detection

S London, 2010 Mar 10, Elsevier Global Medical News

SAN FRANCISCO (EGMN) - A new urinary assay for a common gene rearrangement in prostate cancer improves the detection of this disease and the differentiation of its more aggressive forms, according to two...

Will Cabazitaxel Success Derail Other Prostate Cancer Trials?

E Hayes, 2010 Mar 10, The Pink Sheet Daily

The release of positive Phase III results for Sanofi-Aventis' next-generation chemotherapy agent cabazitaxel in hormone resistant prostate cancer could put a damper on recruitment for clinical trials of...

« start ‹ previous ... 1 2 ... next › end »

Page 1 of 2

Comment Print page RSS feeds

Sign up for our newsletters

Too busy to follow cancer's top stories? Sign-up for one or more of our leading newsletters -- delivered weekly to your inbox.

Advisory and Editorial Boards

Meet OncologySTAT's Advisory and Editorial Boards that represent community practitioners and academic specialists with cross-disciplinary expertise.

Editorial Board › Advisory Board ›